Review for 10.1186/s12876-020-01370-4 (2020)

Reviewer ’s report  
 
Title: Rescue therapy with rifabutin regimen for refra ctory Helicoba cter pylori infection with 
dual drug-resistant strains  
 
Version: 0 Date: 15 Jun 2020  
 
Reviewer's report:  
 
This aim of this study wa s to investigate the efficacy of rifabutin -based triple therapy for patients 
infected with dual drug -resistant strains to clarithromycin and levofloxacin.  
 
Abstract -Materials and Methods, sentence: Patients infected with dual drug -resistant 
(clarithromycin  and levofloxacin) strains and received rifabutin based triple therapy.....  "and" 
should be removed or write "and receiving".  
 
Since rifabutin is a drug that in theory could have serious adverse events (AE), the section AE 
should be described better in th e text and not only in the table.  
 
English language should be revised.  
 
In the section Discussion the authors should report the limitations of the study. For example, they 
should highlight that although the sample size is small, analyzing the overall liter ature on 
H.pylori treatment with rifabutin this could be an acceptable sample. In fact, we can 
hypothesized that about 5 -10% of H.pylori infected patients need to be treated with rifabutin.   
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manus cript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please speci fy what aspects require further 
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Needs some language corrections before being published  
 
Declaration of competing interests  
Please complete a declaration of competing inte rests, considering the following questions:  
 
1.  Have you in the past five years received reimbursements, f ees, funding, or salary 
from an organisation that may in any way gain or lose financial ly from the 
publication of this manuscript, either now or in the  future?  
 
2.  Do you hold any stocks or shares in an organisation t hat may in any way gain or 
lose financially from the publication of this manuscript, either now or in the 
future?  
 
3.  Do you hold or are you currently applying for any patents  relating to the content 
of the manuscript?  
 
4.  Have you received reimbursements, fees, funding, or salary from an organization 
that holds or has applied for patents relating to the content of the manuscript?  
 
5.  Do you have any other financial competing interests?  
 
6.  Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have  no competi ng interests' 
below. If you r reply is yes to any, please give details below.  
 
I declare that I have no competing interests  
 
Reviewer Publication Consent. I agree for my report to be made  available under an Open 
Access Creative Commons CC -BY License ( http://creativecommons.org/licenses /by/4.0 ) if this 
manuscript  is accepted for publication. Any comments that I do not wish to be included in the 
published  report have been included as confidential comments to the editor, which will not be 
published.  If you are not happy for us to publish th is report, please contact the editorial office 
before completing  the review.  If you wish, you can include your name in your published report. 
Please note you must  decide whether to include your name at the start of the process and confirm 
this decision when ever prompted. If you change your decision later, we will not be able to 
publish your name.  
 
I agree to the terms of the CC -BY 4.0 license; please do not publish my name with my report. 
(default)  
 
Publons Reviewer Recognition . Springer Nature can send verifi cation of this review directly to 
Publons (a subsidiary of Clarivate Analytics). If you would like to take advantage of this service, 
please click on the “Yes” option below. Your name, email  address, title of the reviewed 
manuscript, name of the journal, a nd date of your review submission (the “Review Data ”) will 
then be transmitted to Publons upon publication of the manuscript.  If you have already registered 
at Publons, they will notify you of the receipt of this review and update your profile as per  your 
settings and their policy. If you are not registered with Publons,  you will receive an email from 
them asking you to register in order for them to be able to re cognize your review on your new 
profile page. Publons may use the Review Data to generate derivat ive metadata for the benefit of 
Publons and you as a reviewer, carefully considering the sensi tivity of such information. For 
example, Publons may verify your record as a reviewer by updating  your profile published on its 
webservice if you have registered for such service or help editors t o identify candidate reviewers. 
Please find the details of processing in Publons ’ privacy policy https://publons.com/about/terms  
 
Yes